Telehealth ADHD Prescribing: What Psychiatrists Can Do in Florida

If you’re a psychiatrist or PMHNP wondering whether you can legally prescribe Adderall, Ritalin, or other ADHD medications through telehealth — and what the rules actually are in your state — you’re not alone. The regulatory landscape shifted dramatically during COVID, and now in 2026, providers are navigating a mix of extended federal flexibilities, state-specific rules, and genuine uncertainty about what happens next.

Here’s what you need to know about ADHD telehealth prescribing right now, what’s changed, and how to practice safely and profitably in this environment.

The Short Answer: Yes, But It’s Complicated

As of February 2026, psychiatrists can prescribe Schedule II stimulants (Adderall, Ritalin, Vyvanse, etc.) via telehealth to new patients — but only because federal COVID-era waivers have been extended through the end of 2025, and likely into 2026. The DEA and HHS issued their third temporary extension in November 2024, allowing providers to continue initiating controlled substance prescriptions through video visits without an initial in-person exam.

What that means practically:

• You can conduct a comprehensive ADHD evaluation via video
• You can e-prescribe stimulants to a patient you’ve never met in person
• You must still meet the standard of care (thorough assessment, documentation, informed consent)
• You need to be licensed in the state where your patient is located
• You must comply with state-specific telehealth and prescribing rules

The catch: This flexibility exists on temporary extensions. Without new legislation or permanent DEA rules, the Ryan Haight Act’s in-person requirement for controlled substances could snap back into effect, potentially in late 2026 or 2027. Psychiatrists should stay informed and have contingency plans.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal Rules: Where We Are and Where We’re Headed

The Ryan Haight Act Background

Before COVID, the Ryan Haight Act (2008) required at least one in-person medical evaluation before any practitioner could prescribe Schedule II-V controlled substances via telemedicine. This was designed to prevent ‘pill mills’ operating entirely online.

When the pandemic hit, that rule became a massive barrier to care. The DEA used its emergency authority to waive the in-person requirement for controlled substances prescribed for legitimate medical purposes during the Public Health Emergency.

The Current Extension (Through 2025)

In November 2024, the DEA and HHS extended COVID-era telehealth prescribing flexibilities through December 31, 2025. This was the third such extension, buying Congress and regulators more time to craft permanent rules.

What this means for you:

• Through at least the end of 2025, you can initiate stimulant prescriptions via telehealth for ADHD patients
• No in-person visit required before the first prescription
• Standard prescribing protocols apply (DEA registration, state license, PDMP checks, appropriate evaluation)

What Happens After 2025?

No one knows for certain. Three possibilities:

1. Congress passes permanent telehealth legislation that allows controlled substance prescribing with certain guardrails (special registration, training requirements, etc.)
2. DEA issues final rules creating a ‘telemedicine special registration’ pathway for providers to prescribe controlled substances online indefinitely
3. Nothing happens, and the Ryan Haight Act’s in-person requirement returns in 2026

Option 3 would be disruptive — millions of patients now receive ADHD care via telehealth, and forcing in-person visits would create access barriers again. But regulatory inertia is real, so psychiatrists should monitor DEA announcements closely throughout 2026.

Practical tip: If you’re building a telehealth ADHD practice, consider partnering with local clinics or practices that could provide in-person evaluations if needed. This gives you a backup plan without disrupting patient care.

State-by-State Rules: Where Scope of Practice Gets Tricky

Federal law sets the floor, but states add their own layers. Here’s what matters in six key markets:

California: Progressive, But Transitioning

Psychiatrists (MD/DO): Full prescriptive authority. No state-level restrictions on telehealth ADHD prescribing beyond following federal rules.

PMHNPs: California is transitioning to full practice authority under AB 890. Experienced NPs (3+ years, 4,600+ hours) can now apply for independent ‘104 NP’ status and prescribe Schedule II stimulants without physician oversight. Newer NPs still need physician collaboration.

Key requirement: NPs must complete a pharmacology course covering Schedule II medications to prescribe stimulants.

Telehealth: California explicitly allows telehealth prescribing of controlled substances for psychiatric conditions. The state mandates e-prescribing for all controlled substances (since 2022), so you’ll need an EPCS-compliant platform.

Market reality: High demand in metro areas (SF, LA), severe shortages in rural/Central Valley. Competitive provider market in cities; opportunity in underserved areas. Strong insurance coverage and telehealth parity.

Texas: Psychiatrist Territory

Psychiatrists: Full authority. Texas allows telehealth prescribing of controlled substances for mental health conditions via live video (not for chronic pain management, but ADHD doesn’t fall under that restriction).

PMHNPs: This is where Texas gets restrictive. NPs cannot prescribe Schedule II stimulants for outpatient ADHD patients in Texas — period. State law limits NP Schedule II prescribing to hospital inpatients, hospice, or emergency settings only.

Even with a collaborative agreement, an NP cannot write an Adderall prescription for a routine ADHD patient at home. Only physicians (MD/DO) can do this in Texas.

Why this matters: Texas has one of the worst psychiatrist shortages in the country (1 per ~9,000 residents, rank 43rd nationally). The NP restriction means psychiatrists are in extremely high demand for ADHD care. If you’re an MD licensed in Texas, you can build a full caseload quickly.

Collaborative agreements: Physicians can supervise up to 7 NPs in Texas, but since those NPs can’t prescribe stimulants, the workflow usually involves the NP handling therapy/follow-up while the psychiatrist manages medication prescribing.

Market reality: Massive unmet need, especially in rural counties (185 of Texas’s 254 counties are mental health shortage areas). Telehealth is vital. High scrutiny on controlled substance prescribing — Texas legislators have raised concerns about online overprescribing, so practice conservatively and document thoroughly.

Florida: Psychiatric Exception Makes It Work

Psychiatrists: Full authority. Florida statute explicitly allows telehealth prescribing of Schedule II controlled substances when treating psychiatric disorders. ADHD clearly qualifies, so Florida-licensed psychiatrists can prescribe stimulants via video without additional barriers.

PMHNPs: Florida requires physician supervision (collaborative protocol). Here’s the twist: Florida law normally limits NPs to 7-day supplies of Schedule II drugs, but psychiatric nurses working under a psychiatrist’s protocol are exempt from that limit.

A PMHNP in Florida can prescribe 30-day stimulant prescriptions for ADHD patients as long as they have a collaborative agreement with a psychiatrist.

Key requirement: The collaborating physician must be a psychiatrist (not just any MD). Florida defines ‘psychiatric nurse’ specifically as an APRN with mental health certification working under a psychiatrist’s protocol.

Telehealth: One of the most permissive states. Florida Statute 456.47 explicitly allows tele-prescribing of Schedule IIs for psychiatric disorders. Must use PDMP (E-FORCSE) before prescribing.

Market reality: Severe psychiatrist shortage (1 per ~8,500 residents, rank 42nd). South Florida has providers; North Florida and interior are underserved. High patient demand, growing telehealth acceptance. Reimbursement slightly lower than Northeast states but telehealth parity ensures fair payment.

New York: NP-Friendly After Experience

Psychiatrists: Full authority, no restrictions.

PMHNPs: New York uses a transitional independence model. New NPs must practice under a collaborative agreement for 3,600 hours (roughly 2 years). After that, they can apply for full independent practice — no ongoing physician oversight required.

Once independent, NY NPs can prescribe Schedule II stimulants just like psychiatrists. During the collaboration period, NPs can still prescribe stimulants but the agreement should be in place.

Key requirements:

• Mandatory e-prescribing for all controlled substances (since 2016)
• Must check the state Prescription Monitoring Program (I-STOP) before prescribing any Schedule II-IV drug — every single time

Telehealth: No state barriers beyond federal rules. Strong telehealth parity laws. Medicaid covers telepsychiatry at equal rates.

Market reality: Best psychiatrist-to-population ratio in the country (1 per ~2,900 residents), but concentrated in NYC. Upstate and rural areas still underserved. High competition in NYC; easier market penetration upstate. Tech-savvy patient base, strong demand for adult ADHD services especially in young professional population.

Pennsylvania: Extra Steps for NPs

Psychiatrists: Full authority, no limitations.

PMHNPs: Pennsylvania requires collaborative agreements with physicians. Here’s where it gets procedurally complicated: NPs can only prescribe 72 hours of a Schedule II medication for initial therapy with a new patient or new condition. They must notify the collaborating physician within 24 hours.

For ongoing therapy, NPs can prescribe 30-day supplies, but the patient technically should be re-evaluated by the physician before refills continue indefinitely.

Practical workflow: Many PA practices have the psychiatrist do the initial ADHD evaluation and first prescription, then the NP handles monthly follow-ups and refills. This avoids the 72-hour limitation.

Telehealth: No state prohibition on controlled substance tele-prescribing. PA follows federal rules. Telehealth parity through regulatory guidance (though comprehensive telehealth statute still pending in legislature).

Market reality: Moderate psychiatrist supply in Philadelphia and Pittsburgh; shortages in rural central and northern PA. Growing telehealth adoption. Parity coverage from major insurers. The NP limitation creates workflow friction but doesn’t prohibit ADHD care — just requires physician-NP coordination.

Illinois: Path to NP Independence

Psychiatrists: Full authority.

PMHNPs: Illinois allows NPs to obtain Full Practice Authority after completing 4,000 hours of clinical practice plus 250 hours of additional training. Once granted FPA, Illinois NPs can prescribe Schedule II stimulants independently without a collaborative agreement.

Before FPA, NPs need a Written Collaborative Agreement with a physician that specifies prescriptive authority (including Schedule IIs if approved).

Key detail: Illinois law requires physician consultation for NP prescribing of Schedule II narcotics (opioids), but this doesn’t apply to stimulants. FPA-certified PMHNPs can manage ADHD independently.

Telehealth: Strong support. Illinois passed telehealth parity laws in 2021. Mandatory e-prescribing for all controlled substances (since 2023). Must document patient consent for telehealth.

Market reality: Moderate overall psychiatrist supply (1 per ~5,800 residents), heavily concentrated in Chicago. Downstate Illinois faces shortages. Growing number of independent PMHNPs as FPA licenses increase. Strong Medicaid telehealth coverage. Good market for building ADHD practice outside Chicago metro.

PMHNP vs Psychiatrist: What You Can Actually Do

Psychiatrists (MD/DO)

What you can do:

• Practice independently in all 50 states
• Prescribe any Schedule II-V medication without supervision
• Conduct telehealth ADHD evaluations and initiate treatment remotely (under current federal flexibilities)
• Work across state lines if you hold multiple state licenses
• Bill at highest reimbursement rates ($89-95 for 99213, $125+ for 99214 from Medicare)

Workflow advantages:

• No collaborative agreements to negotiate
• No prescription quantity limits (beyond standard 30-day DEA guidance for Schedule IIs)
• Can open independent telehealth practice or join platforms immediately
• Especially valuable in restricted states (TX, FL, PA) where NPs face limitations

Psychiatric Nurse Practitioners (PMHNP)

What you can do (depends heavily on state):

Full Practice Authority states (NY after 3,600 hrs, IL with FPA, CA with 104 status):

• Everything a psychiatrist can do for ADHD prescribing
• Independent practice, no physician oversight required
• Full Schedule II prescribing authority
• Same reimbursement (or 85% under Medicare if billing independently)

Restricted Practice states (TX, FL, PA):

• Must have collaborative agreement with physician (usually psychiatrist)
• May face prescription quantity limits (PA: 72-hour initial, FL: 7-day general limit with psychiatric nurse exception)
• Texas: Cannot prescribe outpatient Schedule II stimulants at all
• Depends on collaborating physician’s willingness to delegate authority
• May need physician to handle initial prescriptions or complex cases

Collaborative agreements: In restricted states, the agreement specifies what you can prescribe. Most psychiatrists will allow PMHNPs to prescribe ADHD meds within protocol, but you’re legally dependent on maintaining that relationship.

The Economic Reality

For Psychiatrists: You’re the bottleneck resource in ADHD care, especially in states with NP restrictions. Telehealth platforms need psychiatrists to cover states like Texas. This translates to strong negotiating power, full schedules, and the ability to command higher per-visit rates.

For PMHNPs: In FPA states, you can compete directly with psychiatrists for ADHD patients. In restricted states, you need an MD partner but can still build a thriving practice handling volume while the psychiatrist focuses on complex cases or provides oversight. The key is knowing your state’s rules before you sign up for a telehealth platform.

Reimbursement: What You’ll Actually Get Paid

Good news: telehealth reimbursement parity is nearly universal as of 2026. After years of temporary extensions, most states have made telehealth payment parity permanent or at least continued it through insurer policy.

Medicare Rates (2024-2025 fee schedule)

Medication management visits:

• 99213 (15-minute established patient visit): ~$89-95
• 99214 (25-minute moderate complexity visit): ~$125-136
• Initial psychiatric evaluation (90792): ~$188-202

Medicare pays the same for telehealth as in-person (non-facility rate) for mental health services. Extensions through at least 2024 made this permanent, with strong Congressional support for continuation.

Private Insurance

Commercial payers typically match or exceed Medicare rates. Depending on your contract and region:

• 99213: $95-130
• 99214: $130-180
• Initial eval: $180-300+

California, New York, Illinois: Higher rates due to cost-of-living adjustments in fee schedules

Texas, Florida, Pennsylvania: Closer to Medicare rates but still fair compensation

Medicaid

Significantly lower — roughly 50% of Medicare rates in many states:

• 99213: ~$40-65
• 99214: ~$60-90

Medicaid does cover telepsychiatry at parity in most states now. If you take Medicaid, expect lower per-visit revenue but often higher volume (long waitlists for care).

Psychiatrists vs Other Providers

Psychiatrists (MD/DO) are reimbursed at the highest rates for psychiatric services. NPs billing independently get 85% of the physician fee schedule under Medicare (many private insurers follow similar structure). However, NPs often bill under collaborative physician oversight at full rates in practice settings.

Practical math: If you see four 15-minute ADHD med checks per hour at Medicare rates (4 × $90 = $360/hour gross), and you can fill a 30-hour clinical week, that’s $10,800/week or ~$560,000 annually before overhead. Telehealth overhead is minimal (no office rent, lower malpractice premiums for some), so net income is strong.

The Platform Economics Question

Many telehealth companies offer two models:

1. Insurance billing: You see patients, platform handles billing/credentialing, you get paid percentage of collections or per-visit rate
2. Cash/subscription model: Patients pay directly (often $99-199 for initial visit, $79-149 for follow-ups), platform takes cut

For ADHD medication management, insurance-based models are often more sustainable long-term (patients need ongoing monthly visits; paying cash adds up). Parity laws ensure you get paid fairly.

The Real Business Case: DIY Marketing vs Platform

Here’s where many providers get the calculation wrong when evaluating telehealth opportunities.

The True Cost of Acquiring ADHD Patients Yourself

Let’s be honest about DIY marketing costs:

Google Ads/PPC:

• Mental health keywords cost $15-40+ per click
• Conversion rate from click to booked appointment: 5-10% if you’re good
• Realistic cost per booked patient: $200-400+
• That assumes you already have a website, scheduling system, payment processing, and ad expertise

SEO (Organic Search):

• Requires 6-12 months of consistent investment before meaningful patient flow
• Monthly costs: $2,000-5,000 for content, technical SEO, backlinks (if outsourced)
• Most solo providers don’t have the patience or expertise for this
• Eventually cost-effective, but long runway to ROI

Directory Listings (Psychology Today, Zocdoc, etc.):

• Psychology Today: Free basic listing, but you’re one of hundreds on search results
• Zocdoc: ~$35-100+ per booking PLUS monthly subscription ($250-500/month)
• You pay whether the patient shows up or not
• Total monthly cost can hit $1,500-3,000 if you book 20-30 patients/month

The Hidden Costs:

• Staff time to answer calls, vet leads, handle no-shows
• Failed campaigns (testing ads, landing pages)
• No-show rates from cold leads (20-30% typical)
• Your own time learning marketing instead of seeing patients

Reality check: Most solo providers who try DIY marketing spend $3,000-5,000/month with uncertain results for the first 6-12 months. That’s $36,000-60,000 before you consistently acquire patients profitably.

The Platform Model: Guaranteed ROI

Compare that to a platform like Klarity:

How it works:

• No upfront marketing spend
• No monthly subscription fees
• Pay a standard per-appointment listing fee when a qualified patient books
• Patients are pre-screened, matched to your specialty and availability
• Built-in telehealth infrastructure (no separate EMR/video platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The economic advantage:

Instead of gambling $3,000-5,000/month on marketing that might work, you pay only when a qualified ADHD patient actually shows up for an appointment. That’s guaranteed ROI — you know exactly what each patient costs, and you only pay when you deliver care and get paid by the patient/insurer.

For established providers: A platform gives you immediate patient flow while you build your own marketing. You’re not choosing platform OR DIY forever — you can do both and optimize over time.

For new providers or those expanding into telehealth: A platform eliminates the biggest barrier (patient acquisition) and lets you focus on clinical work. Once you’re busy and cash flow positive, you can invest in longer-term marketing if you want.

The Math That Matters

Scenario 1: DIY from scratch

• Month 1-6: Spend $4,000/month on marketing, see 10-15 patients/month initially
• Total investment: $24,000
• Net revenue (after marketing costs): Minimal or negative
• Months 7-12: If things work, maybe 30-40 patients/month, still spending $3,000/month
• Break-even: 8-12 months if you’re lucky

Scenario 2: Join platform like Klarity

• Month 1: See 20-30 patients (platform matches you with existing demand)
• Pay per-appointment fee on each (let’s say equivalent to $80-120 per patient depending on model)
• Net revenue after platform fee: $2,400-4,500 in Month 1
• No risk — you only paid for patients you actually saw
• Scale up to 50+ patients/month quickly if you want volume

The question isn’t whether platform fees are lower than DIY marketing (they’re not, per patient, long-term). The question is: Can you afford to burn $30,000-50,000 and 6-12 months building your own patient pipeline, or would you rather start seeing patients and earning immediately?

For most providers, especially early in telehealth, the platform model is the smart financial choice. And you’re not locked in — treat it as a bridge to financial stability while you build other channels.

Clinical Workflows: Doing ADHD Care Right Via Telehealth

The regulations allow it, the economics work — but how do you actually practice quality ADHD care through a screen?

Initial Evaluation (45-60 minutes)

Standard components:

• Comprehensive psychiatric history (childhood symptoms, school/work performance, family history)
• DSM-5 criteria assessment (inattention, hyperactivity-impulsivity symptoms)
• Collateral information (rating scales like ASRS for adults, Vanderbilt for kids; school reports; partner/parent input)
• Differential diagnosis (rule out anxiety, depression, bipolar, substance use, sleep disorders)
• Mental status exam via video (attention, concentration, impulse control observation)
• Medical history and baseline vitals (many providers ask patients to take their own blood pressure or visit a pharmacy with a BP machine)
• Review risks/benefits of stimulant therapy, informed consent

Documentation essentials:

• Patient location (state) for licensure compliance
• Identity verification (match ID to video, state where patient is physically located)
• Evidence supporting ADHD diagnosis (specific symptoms meeting DSM criteria)
• Rationale for medication choice
• Discussion of alternatives (behavioral therapy, non-stimulant meds)
• Consent for telehealth and for controlled substance treatment

Billing: Usually 90792 (psych eval with medical services) — reimburses $180-200+ from Medicare, more from commercial insurance.

Follow-Up Visits (10-15 minutes monthly)

Typical structure:

• Symptom response (attention, focus, task completion)
• Side effect monitoring (appetite, sleep, heart rate/BP, mood changes)
• Medication adherence check
• Functional outcomes (work/school performance, relationships)
• PDMP check (at least quarterly, more often if any red flags)
• Prescription refill (30-day supply, e-prescribed)

Billing: 99213 (15-min) or 99214 (25-min if more complex) — $89-125+ from Medicare

Key compliance points:

• Schedule regular monthly visits (stimulants can’t have refills; each month needs a new script)
• Document each encounter (chief complaint, any changes, clinical decision-making)
• Monitor for signs of misuse/diversion (inconsistent symptom reports, requests for early refills, ‘lost’ medications)
• Coordinate with patient’s PCP if they have cardiac risk factors

What You Can Do Remotely (Almost Everything)

Diagnosis: ADHD is a clinical diagnosis based on history and observation. Video allows you to observe behavioral patterns, attention during conversation, and complete rating scales electronically.

Physical exam elements: Minimal for ADHD. You need baseline vitals (ask patient to provide from PCP visit or home monitoring) and general appearance/mental status (easily observed via video).

Medication management: E-prescribing handles stimulants through EPCS-certified platforms. Dose adjustments, switching meds, adding non-stimulant adjuncts — all can be done remotely.

Labs/testing: If needed (e.g., baseline EKG in patient >40 with cardiac history, liver function if using Strattera), order through LabCorp/Quest and patient goes locally. Not routinely required for ADHD.

What You Can’t Do Remotely

Honestly? Not much for ADHD specifically. You can’t:

• Administer an intramuscular injection (not relevant for ADHD meds)
• Do a hands-on neurological exam (rarely needed for straightforward ADHD)
• Physically hand a patient a prescription (but e-prescribing is better anyway)

The limitation isn’t clinical capability — it’s regulatory uncertainty if federal flexibilities expire.

Best Practices to Avoid ‘Pill Mill’ Perception

Given past scandals with online stimulant prescribing, protect yourself:

Do:

• Conduct thorough evaluations (45+ minutes initially)
• Require collateral information (rating scales, school/work documentation)
• Document specific DSM-5 criteria met
• Schedule regular monthly follow-ups
• Check PDMP consistently
• Use informed consent discussing risks
• Decline to prescribe if evaluation doesn’t support ADHD diagnosis
• Consider non-stimulant alternatives when appropriate (Strattera, Wellbutrin, Qelbree)

Don’t:

• Prescribe stimulants based solely on patient self-report without objective assessment
• Skip PDMP checks
• Allow early refills without documented reason
• Prescribe solely based on asynchronous questionnaires (always do live video evaluation)
• Ignore red flags (patient requesting specific doses, diversion concerns)

The goal: practice the same standard of care you would in-person, just through a different modality.

Medication Shortages: The Reality You’re Walking Into

Since late 2022, ADHD medication shortages have been widespread — particularly for Adderall (amphetamine salts) and its generics. This has been driven by:

1. Surge in demand: Adult ADHD diagnoses and treatment increased significantly during pandemic (easier access via telehealth, reduced stigma)
2. DEA production quotas: The DEA sets manufacturing limits for controlled substances; they’ve been slow to increase quotas despite demand
3. Supply chain issues: Manufacturing delays, raw material shortages

What this means for your practice:

You will have frustrated patients. Many will tell you they’ve called 10 pharmacies and can’t fill their prescription. Some will ask you to switch meds or increase doses when they finally get partial fills.

Practical strategies:

• Maintain flexibility: Be prepared to prescribe alternative stimulants (Vyvanse, Ritalin, Focalin) if Adderall is unavailable
• Build pharmacy relationships: Some telehealth platforms partner with specific pharmacies that prioritize filling their prescriptions
• Consider non-stimulants: For some patients, Strattera (atomoxetine) or Qelbree (viloxazine) may be appropriate alternatives during shortages
• Set expectations: Let patients know upfront that shortages are industry-wide, not your practice issue
• Document: Note in chart when prescription changes are due to availability, not clinical reasons

The good news: The DEA increased production quotas for ADHD meds in late 2024, and shortages have started improving. By 2026, availability should normalize, but it remains a consideration.

State Market Conditions: Where the Opportunity Is

Severe Shortage States (Highest Demand)

Texas: 1 psychiatrist per 9,000 residents (rank 43rd), 185/254 counties are shortage areas. Massive telehealth opportunity but NPs can’t prescribe stimulants, so MDs are critical.

Florida: 1 per 8,500 (rank 42nd). Growing population, big demand in North Florida and interior. Permissive telehealth laws make this a prime market.

Moderate Shortage (Still Strong Opportunity)

Pennsylvania: 1 per 4,586 (rank 10th, but very concentrated in Philly/Pittsburgh). Rural areas underserved. Good insurance reimbursement.

Illinois: 1 per 5,849 (rank 18th). Chicago well-served, downstate needs help. Growing NP independence means both MDs and PMHNPs can thrive.

California: 1 per 5,636 (rank 11th). Huge population (40M+) means absolute numbers of underserved patients are massive despite decent ratio. Rural Central Valley/Inland Empire have major gaps.

Provider-Dense Market (Competitive but Huge Volume)

New York: 1 per 2,900 (rank 4th) — best ratio in country, but NYC has so much demand that there’s still opportunity. Upstate is underserved. High reimbursement, educated patient base seeking care.

Bottom line: Every one of these states offers viable telehealth ADHD practice opportunities. Choose based on your licensure, scope of practice (MD vs NP and state rules), and whether you want high-volume competitive markets or underserved areas with less competition.

What to Watch in 2026-2027

Federal telehealth rules: Monitor DEA announcements about permanent telemedicine prescribing rules or Congressional action. If the waiver expires without replacement, you’ll need contingency plans (partnerships with brick-and-mortar clinics for in-person visits).

State scope of practice changes: Several states have pending legislation to expand NP authority (Pennsylvania FPA bills, Texas NP modernization attempts). Also watch for any states restricting telehealth prescribing in reaction to past abuses.

Reimbursement: Current parity seems stable, but watch for any commercial insurers trying to reduce telehealth rates or Medicare making policy changes.

Medication supply: Shortages should continue improving as DEA quotas rise, but monitor FDA/DEA announcements.

The Bottom Line for Providers

If you’re a psychiatrist:

You’re in the driver’s seat. You can practice ADHD telehealth in any state where you hold a license, with essentially no scope limitations beyond standard controlled substance rules. The combination of severe workforce shortages, high patient demand, strong reimbursement, and low overhead makes telehealth ADHD care one of the most economically attractive niches in psychiatry right now.

If you’re a PMHNP:

Your opportunities depend heavily on your state. In full practice states (or states transitioning there), you can compete directly with psychiatrists. In restricted states, you need an MD partner but can still build a thriving practice. Know your state’s rules before committing to a platform, and if you’re in a restricted state, ensure the platform will provide or help you find a collaborating physician.

For both:

The economics favor platforms for getting started or scaling quickly. The marketing cost and time investment to acquire ADHD patients on your own is substantial — typically $3,000-5,000/month for 6-12 months before you see consistent ROI. A platform like Klarity offers immediate patient flow with zero upfront investment: you pay per qualified appointment, control your schedule, and start earning from day one.

That’s not a marketing pitch — it’s the financial reality of patient acquisition in 2026. Whether you eventually build your own marketing channels or stay with a platform long-term, starting with guaranteed patient flow removes the biggest risk and lets you focus on what you’re actually trained to do: provide excellent psychiatric care.

FAQ: ADHD Telehealth Prescribing

Can I prescribe Adderall via telehealth to a patient I’ve never met in person?

Yes, as of February 2026, under extended federal COVID-era flexibilities (through at least end of 2025, likely into 2026). You must conduct a thorough video evaluation meeting standard of care, be licensed in the patient’s state, and comply with all controlled substance prescribing rules. This could change if federal waivers expire and aren’t replaced with permanent rules.

Do state laws override federal telehealth prescribing rules?

States can be more restrictive than federal law, but generally not more permissive for controlled substances. Some states (like Florida for psychiatric disorders, California with no additional barriers) explicitly allow telehealth controlled substance prescribing. Others (like Texas for chronic pain, but not applicable to ADHD) add restrictions. Always follow both federal DEA rules AND your state’s medical/nursing board telehealth guidelines.

Can PMHNPs prescribe ADHD stimulants in all states?

No. It varies dramatically by state:

• Full practice states (NY after experience, IL with FPA, emerging CA): Yes, independently
• Reduced practice states (PA, FL): Yes, but with physician collaboration and sometimes quantity limits
• Severely restricted states (TX): No — NPs cannot prescribe Schedule II stimulants for outpatient ADHD at all

Check your specific state’s NP scope of practice laws and controlled substance prescribing rules.

What happens if federal telehealth flexibilities expire?

If the DEA waiver expires without permanent legislation or rules, the Ryan Haight Act would require an in-person medical evaluation before prescribing controlled substances via telemedicine. This could mean:

• You’d need to see new ADHD patients in person at least once before prescribing stimulants
• OR partner with local clinics/providers who could do the in-person eval, then you handle ongoing telehealth care
• Existing patients already established before the change would likely be grandfathered, but confirm with legal guidance

Do I need to check the PDMP every time I prescribe ADHD medication?

Requirements vary by state:

• Required every time: New York, some other states mandate PDMP check for each Schedule II prescription
• Required at reasonable intervals: Many states require checking at least every 3 months for ongoing controlled substance therapy
• Best practice everywhere: Check PDMP at initial evaluation and periodically (monthly or quarterly) for ongoing patients, regardless of state mandate

Always check your state’s specific PDMP requirements. Many state medical boards now audit PDMP compliance.

How do I handle ADHD medication shortages with patients?

• Set expectations upfront that shortages are an industry issue
• Maintain flexibility to switch between stimulant options (Adderall, Vyvanse, Ritalin, etc.)
• Consider having patients establish relationships with multiple pharmacies
• Be prepared to prescribe non-stimulant alternatives (Strattera

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the